The prevalence, risk factors, and prognostic value of anxiety and depression in refractory or relapsed acute myeloid leukemia patients of North China.
Anxiety
/ epidemiology
China
/ epidemiology
Combined Modality Therapy
Depression
/ epidemiology
Female
Follow-Up Studies
Humans
Incidence
Leukemia, Myeloid, Acute
/ complications
Male
Middle Aged
Prevalence
Prognosis
Remission Induction
/ methods
Retrospective Studies
Risk Assessment
/ methods
Risk Factors
Journal
Medicine
ISSN: 1536-5964
Titre abrégé: Medicine (Baltimore)
Pays: United States
ID NLM: 2985248R
Informations de publication
Date de publication:
Dec 2019
Dec 2019
Historique:
entrez:
20
12
2019
pubmed:
20
12
2019
medline:
31
12
2019
Statut:
ppublish
Résumé
This study aimed at investigating the prevalence of anxiety and depression, and their risk factors as well as their correlation with prognosis in refractory or relapsed (R/R) acute myeloid leukemia (AML) patients.A total of 180 R/R AML patients were enrolled and their anxiety and depression were assessed by Hospital Anxiety and Depression Scale (HADS) before treatment. Besides, HADS was also evaluated in 180 de novo AML patients prior treatment and 180 healthy controls (HCs), respectively.Both the HADS-Anxiety and HADS-Depression scores were increased in R/R AML patients compared with de novo AML patients and HCs (all P < .001). Meanwhile, the prevalence of anxiety and depression was 53.9% and 45.6% in R/R AML patients, which were also greatly higher compared with de novo AML patients and HCs (all P < .01). Regarding risk factors, higher Eastern Cooperative Oncology Group score and lines of salvage therapy were correlated with anxiety and depression in R/R AML patients (all P < .05). Furthermore, anxiety and depression were associated with shorter overall survival (OS) in R/R AML patients (all P < .05), while no association of different degrees of anxiety and depression with OS was observed (all P > .05).Anxiety and depression are highly prevalent and implicated in the management and prognosis of R/R AML.
Identifiants
pubmed: 31852076
doi: 10.1097/MD.0000000000018196
pii: 00005792-201912130-00016
pmc: PMC6922593
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e18196Références
Am J Manag Care. 2000 Oct;6(18 Suppl):S975-85
pubmed: 11184568
Curr Opin Oncol. 2017 Nov;29(6):467-473
pubmed: 28857842
Blood. 2010 Jan 21;115(3):453-74
pubmed: 19880497
Cancer. 2016 May 15;122(10):1608-17
pubmed: 27028090
Ther Adv Hematol. 2017 Jun;8(6):185-195
pubmed: 28567238
J Affect Disord. 2014 Aug;165:176-81
pubmed: 24882197
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Leuk Res. 2016 Aug;47:142-8
pubmed: 27337292
Ann Hematol. 2008 Apr;87(4):305-10
pubmed: 18219486
Psychosom Med. 1994 Sep-Oct;56(5):432-9
pubmed: 7809343
Curr Geriatr Rep. 2017 Dec;6(4):247-254
pubmed: 29479516
Psychol Med. 2010 Nov;40(11):1797-810
pubmed: 20085667
Clinicoecon Outcomes Res. 2019 Jan 14;11:87-98
pubmed: 30679915
Curr Treat Options Oncol. 2017 Mar;18(3):17
pubmed: 28286924
Turk J Haematol. 2016 Dec 1;33(4):326-330
pubmed: 27094799
Psychosomatics. 1991 Fall;32(4):420-5
pubmed: 1961856
J Psychosom Res. 2003 Apr;54(4):289-92
pubmed: 12670604
Iran J Nurs Midwifery Res. 2014 Jan;19(1):88-93
pubmed: 24554966
Int J Psychiatry Med. 2012;44(2):149-63
pubmed: 23413662
Ann Oncol. 2010 May;21 Suppl 5:v158-61
pubmed: 20555069
Leukemia. 2019 Oct;33(10):2393-2402
pubmed: 30923318
Cancer Treat Rev. 2004 Feb;30(1):103-17
pubmed: 14766128
Cancer Treat Rev. 2018 Sep;69:224-232
pubmed: 30098484
Haematologica. 2004 Aug;89(8):998-1008
pubmed: 15339685
Cancer Nurs. 2014 Mar-Apr;37(2):114-25
pubmed: 23619331
Saudi Med J. 2016 Aug;37(8):877-81
pubmed: 27464865